Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
NCT02384759
Interventional
Phase 2
Completed
FOLFA
This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.
May 31,2015
All
65 Years
N/A
65 Years
N/A
117